Anesc Research — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$283,586	53
2024	Research	$338,147	32

Breakdown

Who paid Research payments · program years 2024–2025

AbbVie, Inc. $212,257 29 payments
Eli Lilly and Company $167,475 8 payments
Pfizer Inc. $68,008 18 payments
E.R. Squibb & Sons, L.L.C. $64,769 3 payments
Genzyme Corporation $51,188 2 payments
Moderna TX, Inc. $40,629 18 payments
Celgene Corporation $16,700 1 payment
Kedrion Biopharma, Inc. $708 6 payments

Studies the money was for Research payments · program years 2024–2025

Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease $183,342 25 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $71,165 1 payment
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $51,188 2 payments
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $43,864 2 payments
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years $40,629 18 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $35,681 1 payment
Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $34,510 13 payments
Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $33,498 5 payments
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $26,866 1 payment
An Adaptive Phase 2A/2B, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of Ly3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis $26,765 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.